Tuberculosis trials and consortium services

Active Definitive Contract Awarded Last action

Contract number
75D30121C10166
Awardee
Awarding agency
Obligated
$2,550,129

Award facts

Opportunity
Contract value 66% obligated
  • $2,640,484.28 Current, with exercised options
  • $3,870,580.28 Potential, with all options
Completion date 59% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 22 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Denver, CO 80204, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Exercise an Option P00011 $389,100
Other Administrative Action P00010 · EO 14398 $0
Exercise an Option P00008 $379,142
Exercise an Option P00007 $369,468
Other Administrative Action P00006 -$19,895
Supplemental Agreement for work within scope P00005 $405,000
Exercise an Option P00004 $350,967
Supplemental Agreement for work within scope P00003 $0
Exercise an Option P00002 $342,116
Supplemental Agreement for work within scope P00001 $0
Original award $334,231
Show all 11

About this award

The Centers for Disease Control and Prevention awarded a $3.87 million definitive cost-no-fee contract to Denver Health And Hospital Authority on December 17, 2020, for tuberculosis trials and consortium services, under no set-aside. The award is recorded under CDC Pittsburgh, and place of performance is Denver, Colorado 80204. Ultimate completion is December 31, 2030.

The originating pre-solicitation, posted February 5, 2020 with a February 14, 2020 response deadline, sought ten years of clinical research support for tuberculosis treatment, diagnosis, and prevention trials. Required services include participation in clinical research studies, adherence to study start-up procedures, and membership in the Tuberculosis Trials Consortium as a member site. Evaluation considered a vendor's ability to concurrently perform multiple clinical trials and studies under approved protocols. The government estimated initiating up to four new studies between the base year and ninth option year, with each phase supporting zero to two new studies alongside continuing enrollment, treatment, testing, and follow-up.

Vanderbilt University Medical Center holds a subcontract dated March 19, 2025, for Tuberculosis Trials Consortium clinical research services covering protocol chair and sub-chair support.

Service Contract Inventory reporting shows government-invoiced labor of $450 thousand in FY2022 across 1.4 FTEs and 2,983 contractor hours, a derived rate of $150.82 per hour, and $749 thousand in FY2024 across 1.8 FTEs and 3,631 contractor hours, a derived rate of $206.16 per hour. FY2021 reflects 1.3 FTEs and 2,664 contractor hours. The trend across reported years is mixed. The prime self-performed all reported FY2024 hours with no subcontractors reported. FY2021 inventories are civilian-only, so cross-year comparisons spanning that cutover are approximate.

Subawards

Subcontractor Amount Awarded
Vanderbilt University Medical Center TUBERCULOSIS TRIALS AND CONSORTIUM SERVICES Tuberculosis Trials Consortium (TBTC) Clinical Research Services - services for protocol chair/sub-chair $141,852

Quick answers

Who was awarded contract 75D30121C10166?

75D30121C10166 was awarded to Denver Health And Hospital Authority by CDC Pittsburgh (Centers for Disease Control and Prevention) on December 17, 2020.

How much is contract 75D30121C10166 worth?

The government has obligated $2,550,129 on 75D30121C10166. Its current value, with exercised options, is $2,640,484. Its potential value, with all options, is $3,870,580.

Was contract 75D30121C10166 competed?

The extent of competition for 75D30121C10166 was full and open competition. The government received 22 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award